LEGENDARY ACQUITY PERFORMANCE
In 2004, ACQUITY UPLC® gave future-focused labs the highest level of chromatographic performance the world had ever seen. Then came a dramatically greater demand for better results in less time. And UPLC® quickly went from leading-edge luxury to global necessity
LEGENDARY ACQUITY PERFORMANCE.AT EVERY LEVEL FOR EVERY LAB.
In 2004, ACQUITY UPLC® gave future-focused labs the highest level of chromatographic performance the world had ever seen. Then came a dramatically greater demand for better results in less time. And UPLC® quickly went from leading-edge luxury to global necessity.
Today, Waters meets the ever-growing demand for higher levels of resolution and sensitivity with an ever-growing family of ACQUITY® Systems. That means for virtually any application, in every analytical lab, all over the world, there’s an ACQUITY System that’s right for you. To find the one that’s right for your lab, visit waters.com/ACQUITY.
Corporate Headquarters
Waters Corporation
34 Maple Street
Milford, MA 01757
T: 508-478-2000 or 1-800-252-4752
F: 508-872-1990
European Headquarters
Waters S.A.S.
BP 608
78056 Saint-Quentin
En Yvelines Cedex, France
T: 33 1 30 48 72 00
F: 33 1 30 48 72 01
www.waters.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
